Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suzanne Reeves

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Communications Biology|September 8, 2022
Changes in dynamic transitions between integrated and segregated states underlie visual hallucinations in Parkinson's diseaseAngeliki Zarkali, Andrea I Luppi, Emmanuel A Stamatakis, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 12, 2022
Selective 5HT3 antagonists and sensory processing: a systematic reviewEirini Tsitsipa, Jonathan Rogers, Sebastian Casalotti, et al.
Alzheimer'S & Dementia (New York, N. Y.)|May 16, 2025
Three approaches to determining clinically meaningful benefit on the Cohen-Mansfield Agitation Inventory in dementia clinical trials for agitationKathy Y Liu, Chineze Ivenso, Rebecca Howard, et al.
Brain Communications|November 10, 2023
Heart rate variability and risk of agitation in Alzheimer's disease: the Atherosclerosis Risk in Communities StudyKathy Y Liu, Eric A Whitsel, Gerardo Heiss, et al.
Journal of Clinical Psychopharmacology|April 8, 2025
Plasma Clozapine in Treatment Refractory Schizophrenia: What Is the Target Range?Robert James Flanagan, Stephen John Obee, Alice Hyun Min Kim, et al.
The British Journal of Psychiatry : the Journal of Mental Science|November 12, 2020
Towards safer risperidone prescribing in Alzheimer's diseaseSuzanne Reeves, Julie Bertrand, Hiroyuki Uchida, et al.
Journal of Clinical Psychopharmacology|November 26, 2025
Adverse Reactions to Clozapine: Plasma Clozapine in Relation to Smoking StatusRobert James Flanagan, Jonathan P Rogers, Paula Liren Valbuena Sanchez, et al.
Brain : a Journal of Neurology|March 24, 2017
Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's diseaseSuzanne Reeves, Emma McLachlan, Julie Bertrand, et al.
Fluids and Barriers of the CNS|December 18, 2019
Region-specific blood-brain barrier transporter changes leads to increased sensitivity to amisulpride in Alzheimer's diseaseGayathri Nair Sekhar, Alice L Fleckney, Sevda Tomova Boyanova, et al.
International Journal of Geriatric Psychiatry|June 24, 2017
Therapeutic D2/3 receptor occupancies and response with low amisulpride blood concentrations in very late-onset schizophrenia-like psychosis (VLOSLP)Suzanne Reeves, Kate Eggleston, Elizabeth Cort, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Communications Biology|September 8, 2022
Changes in dynamic transitions between integrated and segregated states underlie visual hallucinations in Parkinson's diseaseAngeliki Zarkali, Andrea I Luppi, Emmanuel A Stamatakis, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 12, 2022
Selective 5HT3 antagonists and sensory processing: a systematic reviewEirini Tsitsipa, Jonathan Rogers, Sebastian Casalotti, et al.
Alzheimer'S & Dementia (New York, N. Y.)|May 16, 2025
Three approaches to determining clinically meaningful benefit on the Cohen-Mansfield Agitation Inventory in dementia clinical trials for agitationKathy Y Liu, Chineze Ivenso, Rebecca Howard, et al.
Brain Communications|November 10, 2023
Heart rate variability and risk of agitation in Alzheimer's disease: the Atherosclerosis Risk in Communities StudyKathy Y Liu, Eric A Whitsel, Gerardo Heiss, et al.
Journal of Clinical Psychopharmacology|April 8, 2025
Plasma Clozapine in Treatment Refractory Schizophrenia: What Is the Target Range?Robert James Flanagan, Stephen John Obee, Alice Hyun Min Kim, et al.
The British Journal of Psychiatry : the Journal of Mental Science|November 12, 2020
Towards safer risperidone prescribing in Alzheimer's diseaseSuzanne Reeves, Julie Bertrand, Hiroyuki Uchida, et al.
Journal of Clinical Psychopharmacology|November 26, 2025
Adverse Reactions to Clozapine: Plasma Clozapine in Relation to Smoking StatusRobert James Flanagan, Jonathan P Rogers, Paula Liren Valbuena Sanchez, et al.
Brain : a Journal of Neurology|March 24, 2017
Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's diseaseSuzanne Reeves, Emma McLachlan, Julie Bertrand, et al.
Fluids and Barriers of the CNS|December 18, 2019
Region-specific blood-brain barrier transporter changes leads to increased sensitivity to amisulpride in Alzheimer's diseaseGayathri Nair Sekhar, Alice L Fleckney, Sevda Tomova Boyanova, et al.
International Journal of Geriatric Psychiatry|June 24, 2017
Therapeutic D2/3 receptor occupancies and response with low amisulpride blood concentrations in very late-onset schizophrenia-like psychosis (VLOSLP)Suzanne Reeves, Kate Eggleston, Elizabeth Cort, et al.
Pageof 5